NCT01381640

Brief Summary

This is a single dose pharmacoscintigraphic study investigating the differences in paracetamol absorption between two formulations.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Apr 2010

Shorter than P25 for phase_1

Geographic Reach
1 country

2 active sites

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2010

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2010

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

June 23, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 27, 2011

Completed
Last Updated

July 6, 2016

Status Verified

July 1, 2016

Enrollment Period

1 month

First QC Date

June 23, 2011

Last Update Submit

July 5, 2016

Conditions

Keywords

paracetamolhealthy volunteerpharmacoscintography

Outcome Measures

Primary Outcomes (1)

  • Time of onset and completion of disintegration based on release of radiolabeled markers in a fed condition

    Baseline to 12 hours post dosing

Secondary Outcomes (1)

  • To assess the gastrointestinal transit by qualitative scintigraphic analysis

    Baseline to 12 hours post dosing

Study Arms (2)

Marketed paracetamol

ACTIVE COMPARATOR

Marketed formulation

Drug: Marketed paracetamol

Experimental paracetamol formulation

EXPERIMENTAL

Experimental formulation

Drug: Experimental paracetamol formulation

Interventions

marketed formulation

Marketed paracetamol

Experimental formulation

Experimental paracetamol formulation

Eligibility Criteria

Age18 Years - 55 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy male subjects who are in good general health
  • Have not exceeded the limits of total radiation exposure (5mSv) allowed in any 12 month period

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

BIO-IMAGES Research Ltd.

Glasgow, Scotland, G63 0BX, United Kingdom

Location

Bio-Images

Glasgow, Scotland, G63 0BX, United Kingdom

Location

Study Officials

  • GSK Clinical Trials

    GlaxoSmithKline

    STUDY DIRECTOR
0

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 23, 2011

First Posted

June 27, 2011

Study Start

April 1, 2010

Primary Completion

May 1, 2010

Study Completion

May 1, 2010

Last Updated

July 6, 2016

Record last verified: 2016-07

Locations